Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?

Two prominent companies with a strong foothold in this space are Hologic HOLX and Myriad Genetics MYGN. Hologic’s molecular diagnostics offerings specialize in women’s health and acute ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to Neutral. Analyst Price Forecast Suggests 107.09% Upside As of April 1, 2025, ...

A month has gone by since the last earnings report for Myriad Genetics (MYGN). Shares have lost about 17.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

Myriad Genetics (NASDAQ:MYGN – Free Report) had its target price cut by The Goldman Sachs Group from $18.00 to $14.00 in a research report report published on Thursday morning,Benzinga reports.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that ...

MYGN has been the topic of several other reports. Bank of America dropped their price target on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a ...